Table.

Clinical features of patients with antisynthetase syndrome treated with anakinra.

	Patient/Cohort	Sex and Age, Yrs	Clinical Manifestations and Antibody Profile	Acute-Phase Reactants and Ferritin Levels	Treatment Prior to Anakinra	Daily Dosage of Anakinra, mg	Concomitant Treatment
Our cohort	Patient 1	Male, 66	Arthritis, fever, ILD, myopericarditis anti-PL12+	Increased	GC	200	GC
	Patient 2	Male, 55	Fever, ILD, myocarditis, rash, Raynaud anti-PL12+	Increased	GC, AZA, MMF	200	GC
	Patient 3	Female, 54	Fever, myocarditis, myositis, rash anti-Jo1+	Increased	GC, IVIG, MTX	200	GC, MTX
Literature review	Furlan⁷	Female, 60	Arthritis, fever, ILD, myositis, rash anti-Jo1+	Increased	GC, CYA, CYC, MTX	100	GC, MTX
	Zong⁸	Male, 54	Clinical manifestations NR anti-Jo1+	NR	AZA, CYC, IFX, IVIG, MTX	100	GC, AZA
	Meudec⁹	Female, 55	Arthritis, ILD, myopericarditis, myositis anti-Jo1+	NR	MTX, RTX	NR	GC, MTX
	Ahmad¹⁰	Female, 65	Arthritis, fever, ILD, rash anti-Jo1+	Increased	AZA, RTX, MMF	100	GC

AZA: azathioprine; CYC: cyclophosphamide; GC: glucocorticoid; IFX: infliximab; ILD: interstitial lung disease; IVIG: intravenous immunoglobulins; MMF: mycophenolate mofetil; MTX: methotrexate; NR: not reported; RTX: rituximab.